Please enable Javascript
Benjamin Maughan, MD, PharmD
Benjamin Maughan, MD, PharmD, of University of Utah Health
Articles by Benjamin Maughan, MD, PharmD
Expanding Treatment Horizons: Novel Approaches in RCC and Non-Clear Cell Disease
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
View More
Multidisciplinary Approaches to Managing IRAEs in RCC
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
View More
From Infusion to Injection: The Promise of Subcutaneous Nivolumab
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
View More
The Role of RCC Second-Line Therapy in Frontline Decision-Making: Does the Approach Matter?
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
View More
COSMIC-313 and the Future of Triplet Therapy in RCC: Efficacy, Toxicity, and Biomarkers
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
View More
Advancing Precision Medicine in RCC: The Role of Biomarkers in Treatment Decisions
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
View More
Refractory RCC: Third-Line Treatment Considerations
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Improving Outcomes in Patients With Chromophobe, Papillary RCC
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
View More
Personalized RCC Care: Decreasing Overtreatment, Identifying Cured Patients in the Adjuvant Setting
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
View More
Considerations for Managing Patients on Maintenance RCC Therapy
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
View More
CheckMate 67T: Do Recent Updates Make This Practice-Changing?
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
View More
RCC Treatment Sequencing and Combination Approaches: JAVELIN Renal 101 and COSMIC-313
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
View More